Search results for "Enthesitis"

showing 9 items of 9 documents

Role of subclinical gut inflammation in the pathogenesis of spondyloarthritis

2018

Subclinical gut inflammation occurring in patients affected by spondyloarthritis (SpA) is correlated with the severity of spine inflammation. Several evidences indicate that dysbiosis occurs in SpA, and that may modulate intestinal permeability and intestinal immune responses. The presence of intestinal dysbiosis is accompanied in SpA patients with the presence of zonulin-dependent alterations of gut-epithelial and gut-vascular barriers. The leakage of epithelial and endothelial surface layers is followed by the translocation of bacterial products, such as lipopolysaccharide and intestinal fatty acid binding protein, in the systemic circulation. These bacterial products may downregulate the…

0301 basic medicineInnate immune responseLipopolysaccharideenthesitis-related arthritisCD14Mini ReviewInflammationInflammation mediator03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemmedicine030203 arthritis & rheumatologyEnthesitis-related arthritilcsh:R5-920Gut microbiomeInnate immune systemIntestinal permeabilitybusiness.industryInnate lymphoid cellGeneral Medicinemedicine.diseaseinflammation mediatorsSettore MED/16 - Reumatologia030104 developmental biologychemistryImmunologyMedicinemedicine.symptombusinesslcsh:Medicine (General)DysbiosisSpondylitis
researchProduct

Achilles tendon ultrasonography may detect early features of psoriatic arthropathy in patients with cutaneous psoriasis.

2014

SummaryBackground Psoriatic arthropathy is a progressive and debilitating disease involving reduction of functional activity of the articulations with consequent deterioration of the patient's quality of life. The entheses represent the initial site of articular inflammation and the enthesis of the Achilles tendon is the first to be affected. In some patients with psoriasis, enthesitis may not be diagnosed because it is still asymptomatic. Objectives To evaluate whether ultrasonography allows early diagnosis in a larger population and to identify significant alterations of enthesitis beyond increased thickness of the Achilles tendon. Materials and methods The study was undertaken on 59 pati…

AdultMalemedicine.medical_specialtyHeelBursitisPopulationDermatologyAchilles TendonYoung AdultPsoriasismedicineHumansPsoriasiseducationAgedUltrasonographyAchilles tendoneducation.field_of_studybusiness.industryArthritis PsoriaticEnthesitisMiddle Agedmedicine.diseaseEnthesisDermatologyTendonSurgerymedicine.anatomical_structureEarly DiagnosisTendinopathyFemalemedicine.symptombusinessThe British journal of dermatology
researchProduct

Increased proportion of comorbidities but no deterioration of sexual quality of life during a 5-year follow-up in patients with axial spondyloarthrit…

2021

Abstract Objective To explore patient perception of sexual quality of life (SQOL), an important category of QOL, in male and female patients with axial SpA (axSpA) after a 5 year follow-up. Methods A broad spectrum of demographic, disease-related, treatment and SQOL data was collected at baseline and at the 5 year follow-up. SQOL was assessed by the SQOL-Female (SQOL-F) questionnaire. For statistical analysis, McNemar’s tests, paired t-tests and multiple regression analyses were applied. Results A total of 245 axSpA patients (168 men and 77 women) from outpatient clinics were examined (mean age 46 years, mean disease duration 11.9 years at baseline). Compared with baseline, the patients had…

AdultMalemedicine.medical_specialtySexual BehaviorDiseaseComorbidityMcNemar's testRheumatologyQuality of lifeInternal medicineSurveys and QuestionnairesSpondylarthritismedicineOutpatient clinicHumansPharmacology (medical)Axial spondyloarthritisAnkylosing spondylitisBiological Productsbusiness.industryEnthesitisMiddle Agedmedicine.diseaseComorbidityAntirheumatic AgentsQuality of LifeFemalemedicine.symptombusinessFollow-Up StudiesRheumatology (Oxford, England)
researchProduct

The relationship between demographic- and disease-related variables and health-related quality of life in patients with axial spondyloarthritis

2017

Background Axial spondyloarthritis (ax-SpA) is a chronic inflammatory disease of the spine causing pain, stiffness, loss in physical function, and fatigue. Therefore, the physical and psychological burden of having this chronic disease can reduce the quality of life. We aimed to explore the relationship between demographic- and disease-related variables and health-related quality of life (HRQoL) in patients with ax-SpA. Methods Demographic- and disease-related, HRQoL-related and treatment data were collected. Disease measures included the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the BAS Functional Index (BASFI), the BAS Global (BAS-G) score, the Maastricht Ankylosing Spo…

AdultMalemedicine.medical_specialtylcsh:Diseases of the musculoskeletal systemSports medicineHealth-related quality of lifeUtility measures03 medical and health sciences0302 clinical medicineRheumatologyQuality of lifeInternal medicineSpondylarthritisEpidemiologymedicineHumansOrthopedics and Sports Medicine030212 general & internal medicineAxial spondyloarthritisBASDAIExerciseAged030203 arthritis & rheumatologyAnkylosing spondylitisbusiness.industryEnthesitisMiddle Agedmedicine.diseaseRheumatologyQuality of LifePhysical therapyFemaleTargeted medicationsmedicine.symptomlcsh:RC925-935BASFIbusinessResearch Article
researchProduct

Reliability, validity and feasibility of nail ultrasonography in psoriatic arthritis

2016

International audience; Objective: To determine the feasibility, reliability and validity of nails ultrasonography in psoriatic arthritis as an outcome measure.Methods: Pilot prospective single-centre study of eight ultrasonography parameters in B mode and power Doppler concerning the distal interphalangeal (DIP) joint, the matrix, the bed and nail plate. Intraobserver and inter-observer reliability was evaluated for the seven quantitative parameters (ICC and kappa). Correlations between ultrasonography and clinical variables were searched to assess external validity. Feasibility was assessed by the time to carry out the examination and the percentage of missing data.Results: Twenty-seven p…

MalecognitionbehaviorsPilot ProjectsNailperceptionfrontotemporal dementia030207 dermatology & venereal diseases0302 clinical medicineProspective StudiesUltrasonographyObserver VariationmechanismsSynovitismedicine.diagnostic_testFeasibilitytoolMiddle AgedNail plateReliability3. Good healthmedicine.anatomical_structure[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemPsoriatic arthritisNail (anatomy)Femalemovementmedicine.symptomAdultmedicine.medical_specialtyPhysical examinationValidity[ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal systemExternal validity03 medical and health sciencesPsoriatic arthritisRheumatologyvisuomotor integrationFinger JointSynovitismedicineHumansAged030203 arthritis & rheumatologybusiness.industryArthritis PsoriaticEnthesitisReproducibility of ResultsapraxiaUltrasonography Dopplermedicine.diseaseSurgeryNailsFeasibility StudiesbusinessNuclear medicineKappaJoint Bone Spine
researchProduct

Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis : 6-year efficac…

2019

Background To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related arthritis (ERA), and psoriatic arthritis (PsA) Methods Patients who completed the 2-year, open-label, phase III CLinical Study In Pediatric Patients of Etanercept for Treatment of ERA, PsA, and Extended Oligoarthritis (CLIPPER) were allowed to enroll in its 8-year long-term extension (CLIPPER2). Children received ETN at a once-weekly dose of 0.8 mg/kg, up to a maximum dose of 50 mg/week. Efficacy assessments included the JIA core set of outcomes, the JIA American College of Rheumatology response criteria (JIA-ACR), and t…

Malelcsh:Diseases of the musculoskeletal systemArthritisCHILDRENCATEGORIESDISEASE-ACTIVITYEtanerceptEtanerceptEnthesitis-related arthritis (ERA)Juvenile Arthritis Disease Activity ScoreDOUBLE-BLINDINITIATIONNECROSIS-FACTORDEFINING CRITERIAMedicine and Health SciencesMedicineChildNon-U.S. Gov'tClinical trial; Efficacy; Enthesitis-related arthritis; Enthesitis-related arthritis (ERA); Etanercept; Extended oligoarticular juvenile idiopathic arthritis (eoJIA); Juvenile idiopathic arthritis; Psoriatic arthritis (PsA); SafetyOligoarthritisResearch Support Non-U.S. Gov'tMETHOTREXATEClinical trialTreatment OutcomeAntirheumatic AgentsChild PreschoolFemaleSafetymedicine.drugResearch Articlemedicine.medical_specialtyAdolescentEfficacyEnthesitis-related arthritisResearch SupportPsoriatic arthritisPsoriatic arthritis (PsA)Internal medicineAdalimumabJournal ArticleHumansetanercept ; juvenile idiopathic arthritis ; enthesitis-related arthritis ; extended oligoarticular juvenile idiopathic arthritis (eoJIA) ; enthesitis-related arthritis (ERA) ; psoriatic arthritis (PsA) ; efficacy ; safety ; clinical trialPEDIATRIC-PATIENTSbusiness.industryJuvenile idiopathic arthritismedicine.diseaseRheumatologyArthritis JuvenileOligoarticular Juvenile Idiopathic Arthritislcsh:RC925-935Extended oligoarticular juvenile idiopathic arthritis (eoJIA)businessADALIMUMAB
researchProduct

Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.

2015

Objective.The main objective was to determine the 2-year clinical benefit and safety of etanercept (ETN) in children with the juvenile idiopathic arthritis (JIA) categories of extended oligoarthritis (eoJIA), enthesitis-related arthritis (ERA), or psoriatic arthritis (PsA).Methods.CLIPPER was a 96-week, phase IIIb, open-label, multicenter study. Patients with eoJIA, ERA, or PsA received ETN 0.8 mg/kg once weekly (50 mg max) for up to 96 weeks. The proportions of patients reaching the JIA American College of Rheumatology (ACR) 30/50/70/90/100 and inactive disease responses at Week 96 were calculated. Adverse events (AE) were collected throughout the study (intention-to-treat sample).Results.…

Malemedicine.medical_specialtyAdolescentEnthesitis-related arthritisImmunologyArthritisJuvenilePsoriaticEtanerceptEtanercept03 medical and health sciencesPsoriatic arthritis0302 clinical medicineRheumatologyInternal medicinemedicineImmunology and AllergyHumans030212 general & internal medicinePreschoolChild030203 arthritis & rheumatologyOligoarthritisbusiness.industryArthritisArthritis PsoriaticClinical trial; Enthesitis-related arthritis; Etanercept; Extended oligoarthritis; Juvenile idiopathic arthritis; Psoriatic arthritis; Adolescent; Antirheumatic Agents; Arthritis Juvenile; Arthritis Psoriatic; Child; Child Preschool; Etanercept; Female; Humans; Male; Treatment OutcomeJuvenile idiopathic arthritismedicine.diseaseRheumatologyPharyngitisArthritis Juvenile3. Good healthSurgeryClinical trialUpper respiratory tract infectionTreatment OutcomePsoriatic arthritisAntirheumatic AgentsChild PreschoolExtended oligoarthritisBronchitisFemalemedicine.symptombusinessmedicine.drugThe Journal of rheumatology
researchProduct

Flare in axial spondyloarthritis. The dark side of the outcome

2016

Spondyloarthritis (SpA) is a chronic inflammatory rheumatic disease with many phenotypes,1 but the frame of the disease is still a matter of debate, particularly regarding the non-radiographic forms of axial SpA.2 ,3 The disease evolution may have several profiles, mainly related to the treatment strategy, balancing from periods of remission or low disease activity to flares of the disease. The recommended treatment strategies are supposed to be tailored to the disease activity, aiming to reach remission or low disease activity in a T2T strategy,4 with management of remission (reduction of dosage or increase in interval of administration), as well as treatment intensification in case of fla…

medicine.medical_specialtyPathologyImmunologyDiseaseInflammatory bowel diseaseGeneral Biochemistry Genetics and Molecular Biologylaw.invention03 medical and health sciences0302 clinical medicineRheumatologylawSynovitisSpondylarthritismedicineHumansImmunology and AllergySpondylitis Ankylosing030212 general & internal medicineIntensive care medicine030203 arthritis & rheumatologyAnkylosing spondylitisbusiness.industryEnthesitismedicine.diseaseConnective tissue diseaseRheumatoid arthritismedicine.symptombusinessFlareAnnals of the Rheumatic Diseases
researchProduct

Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease

2018

Objectives Vedolizumab (VDZ) blocks α4β7 integrin and is licenced for the treatment of IBD. It has been associated with mild SpA-related features, including sacroiliitis and synovitis. Herein we report a series of cases demonstrating the emergence of severe SpA-associated enthesitis/osteitis following successful IBD therapy with VDZ. Methods We evaluated 11 VDZ-treated patients with IBD across seven centres who developed severe active SpA and/or enthesopathy, with the aim of characterizing the VDZ-associated SpA or entheseal flares. Imaging features demonstrating particularly severe disease were recorded. Results De novo SpA developed in 9 of 11 patients and flare of known SpA in 2 patients…

musculoskeletal diseasesvedolizumabmedicine.medical_specialtySpondyloarthropathyenthesitimucosal vascular addressin cell adhesion molecule-1 (MADCAM-1)Vedolizumabulcerative coliti03 medical and health sciences0302 clinical medicineRheumatologyInternal medicinemedicinePharmacology (medical)030212 general & internal medicinespondyloarthritiα4β7 integrin030203 arthritis & rheumatologyCrohn's diseaseAnkylosing spondylitisbusiness.industryEnthesopathySacroiliitisEnthesitismedicine.diseaseankylosing spondylitispondylarthritiCrohn’Osteitismedicine.symptombusinessaxial SpAmedicine.drug
researchProduct